Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin plus G-CSF in cancer patients

被引:7
作者
Joshi, SS
Miller, K
Jackson, JD
Warkentin, P
Kessinger, A
机构
[1] Univ Nebraska, Med Ctr 986395, Dept Cell Biol & Anat, Omaha, NE 68198 USA
[2] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA
[3] Univ Nebraska, Med Ctr, Dept Pediat, Omaha, NE 68198 USA
[4] Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA
关键词
erythropoietin; G-CSF blood stem cells; mobilization; cytotoxic effector cell; functions; phenotypes;
D O I
10.1080/146532400539017
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background Although the recombinant granulocyte colony-stimulating factor (G-CSF) is a good CD34 cell mobilizer; the effects of G-CSF mobilization on the immune effector function of the individual is not always optimal. We studied the functional and phenotypic properties of peripheral blood stem cells (PBSC) collected from 15 cancer patients mobilized with G-CSF plus recombinant erythropoietin (EPO). Methods The patients received EPO (300 U/kg) and (G-CSF 10 mu g/kg) per day as mobilizing cytokines and an autologous graft product was collected with at least daily apheresis procedures until a target number of CD34 cells and mononuclear cells were obtained Mononuclear cells from the first four PBSC collections were tested for their natural killer (NK), activated NK and lymphokine activated killer (LAK) cytotoxicity in vitro against K562 and Raji tumor target cells. Results There was a significant increase in NK, activated NK and LAK cytotoxicity in EPO + G-CSF mobilized cells when compared to mononuclear cells from premobilization blood baseline values Although there was no increase in CD3(+) T cells there was a significant increase in myeloid cells (CD14(+)), B-cells (CD20(+)) and NK cells (CD56(+)) following mobilization. There was no difference in T cell response to the mitogens PHA and Con-A, but there was an increase in B-cell response to PWM following mobilization. Thus, the combination of EPO + G-CSF not only mobilized hematopoietic precursor cells but also increased the number of immune effector cells in the PBSC collections.
引用
收藏
页码:15 / 24
页数:10
相关论文
共 50 条
[31]   Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma [J].
Donato, ML ;
Champlin, RE ;
Van Besien, KW ;
Korbling, M ;
Cabanillas, F ;
Anderlini, P ;
Gajewski, JG ;
Lauppe, J ;
Durett, A ;
Andersson, B ;
Giralt, S ;
Khouri, I ;
Hagemeister, F ;
Romaguera, JE ;
Sarris, A ;
McLaughlin, P ;
Younes, A ;
Ippoliti, C ;
Blamble, DA ;
Hester, J ;
Gee, A ;
Rodriguez, MA .
LEUKEMIA & LYMPHOMA, 1999, 35 (3-4) :317-324
[32]   A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma [J].
Ghobadi, Armin ;
Fiala, Mark A. ;
Rettig, Michael ;
Schroeder, Mark ;
Uy, Geoffrey L. ;
Stockerl-Goldstein, Keith ;
Westervelt, Peter ;
Vij, Ravi ;
DiPersio, John F. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) :E588-E593
[33]   Targeting stem cell niche can protect hematopoietic stem cells from chemotherapy and G-CSF treatment [J].
Li, Sidan ;
Zou, Dehui ;
Li, Changhong ;
Meng, Hengxing ;
Sui, Weiwei ;
Feng, Sizhou ;
Cheng, Tao ;
Zhai, Qiongli ;
Qiu, Lugui .
STEM CELL RESEARCH & THERAPY, 2015, 6
[34]   Feasibility of peripheral blood stem cell collection from sickle cell trait donors with an intensified G-CSF regimen [J].
Mohrez, Morad ;
Troeger, Anja ;
Kleinschmidt, Katharina ;
Alali, Tarek Hanafee ;
Jakob, Marcus ;
Brosig, Andreas ;
Haehnel, Viola ;
Kietz, Silke ;
Offner, Robert ;
Burkhardt, Ralph ;
Corbacioglu, Selim ;
Ahrens, Norbert ;
Foell, Juergen .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (05) :824-830
[35]   Prospective Comparative Study of Etoposide plus G-CSF versus G-CSF Alone, Followed by Risk-Adapted Plerixafor for Peripheral Blood Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma: CAtholic REsearch Network for Multiple Myeloma Study (CAREMM-2001) [J].
Park, Sung-Soo ;
Shin, Seung-Hwan ;
Lee, Jung-Yeon ;
Jeon, Young-Woo ;
Yhang, Seung-Ah ;
Min, Chang-Ki .
CANCERS, 2023, 15 (19)
[36]   Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program [J].
Shaughnessy, P. ;
Uberti, J. ;
Devine, S. ;
Maziarz, R. T. ;
Vose, J. ;
Micallef, I. ;
Jacobsen, E. ;
McCarty, J. ;
Stiff, P. ;
Artz, A. ;
Ball, E. D. ;
Berryman, R. ;
Dugan, M. ;
Joyce, R. ;
Hsu, F. J. ;
Johns, D. ;
McSweeney, P. .
BONE MARROW TRANSPLANTATION, 2013, 48 (06) :777-781
[37]   Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin’s lymphoma and multiple myeloma: results from the expanded access program [J].
P Shaughnessy ;
J Uberti ;
S Devine ;
R T Maziarz ;
J Vose ;
I Micallef ;
E Jacobsen ;
J McCarty ;
P Stiff ;
A Artz ;
E D Ball ;
R Berryman ;
M Dugan ;
R Joyce ;
F J Hsu ;
D Johns ;
P McSweeney .
Bone Marrow Transplantation, 2013, 48 :777-781
[38]   Older Age But Not Donor Health Impairs Allogeneic Granulocyte Colony-Stimulating Factor (G-CSF) Peripheral Blood Stem Cell Mobilization [J].
Richa, Elie. ;
Papari, Mona ;
Allen, JoAnn ;
Martinez, Guadalupe ;
Wickrema, Amittha ;
Anastasi, John ;
Van Besien, Koen ;
Artz, Andrew .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (11) :1394-1399
[39]   Mobilization of peripheral blood progenitor cells with G-CSF alone in lymphoma patients: steady-state circulating progenitor cell count predicts the autograft yield [J].
Grimaz, S ;
Damiani, D ;
Michieli, M ;
Baccarani, M .
HAEMATOLOGICA, 2000, 85 (01) :102-103
[40]   ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m−2 and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients [J].
M J Watts ;
S J Ings ;
D Leverett ;
A MacMillan ;
S Devereux ;
A H Goldstone ;
D C Linch .
British Journal of Cancer, 2000, 82 :278-282